Clinical trials: Androgen Deprivation Therapy
Prostate Cancer
Study of Dasatinib, Androgen Deprivation Therapy and Radiation
Radiation and androgen deprivation is a common modality for patients with localized prostate cancer. Unfortunately for patients with intermediate to high risk prostate cancer incomplete tumor eradication and subsequent relapse…
- Trial name
- BrUOGPR255 (NCT01826838)
- Testing
- Dasatinib
- Sponsor
- Brown University
Prostate Cancer
Med Diet Prevention Metabolic Syndrome Men Undergoing Androgen Deprivation Therapy Prostate Cancer
The purpose of this study is to assess for changes in a patient's overall energy level and well-being (quality of life) after 8 weeks of dietary intervention.
- Trial name
- NCT01083771
- Testing
- Olive Oil
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Brown University
Prostate Cancer
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer. Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized…
- Trial name
- NCT01492972
- Testing
- Radiation, Androgen Suppression Therapy
- Where
- 4 sites in United States
- Volunteers
- 192 people
- Sponsor
- Proton Collaborative Group
Prostate Cancer, Osteoporosis
Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
Androgen deprivation therapy (ADT) treatment for prostate cancer decreases the natural hormone called testosterone. This type of therapy is very effective for the treatment of prostate cancer.
- Conditions
- Prostate Cancer, Osteoporosis, Fractures
- Trial name
- NCT00129142
- Testing
- Toremifene Citrate
- Where
- 155 sites in United States, Mexico
- Volunteers
- 1,200 people
- Sponsor
- GTx
Oligometastatic Hormone-Sensitive Prostate Cancer, Prostate Adenocarcinoma
Prospective Study on the Role of Radical Prostatectomy in Oligo-metastatic Hormone-sensitive Prostate Cancer in Patients on Androgen Deprivation Therapy
MAZINGA is a prospective, single-group pilot study evaluating disease control after robot-assisted radical prostatectomy with extended pelvic lymph-node dissection in men with oligometastatic hormone-sensitive prostate…
- Trial name
- MAZINGA (NCT07766486)
- Testing
- Robot-Assisted Radical Prostatectomy With Extended Pelvic Lymph-Node Dissection
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Androgen Deprivation Therapy, Prostate Cancer
Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
The purpose of this research is to determine whether a 16-week culturally tailored, technology-based, aerobic and resistance exercise intervention improves cardiovascular risk factors in Black men diagnosed with prostate cancer…
- Conditions
- Androgen Deprivation Therapy, Prostate Cancer, Prostate Cancer Metastatic
- Trial name
- NCT05327465
- Testing
- Aerobic and resistance exercise, Usual Care
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate CA
Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate Cancer
The high incidence of prostate cancer is one of the important diseases that threaten the health of old men in our country. Although androgen deprivation therapy is an important treatment option for prostate cancer, although…
- Trial name
- NCT06834321
- Testing
- Homoharringtonine combined with androgen deprivation therapy, radical prostatectomy
- Where
- 2 sites in China
- Volunteers
- 96 people
- Sponsor
- baotai Liang
Prostate Cancer
Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer
The purpose of this study is to determine whether combination treatment of prostate cancer with IMC-A12 (an antibody which blocks insulin-like growth factor receptor activity) with hormonal therapy (testosterone lowering) before…
- Trial name
- NCT00769795
- Testing
- IMC-A12, Bicalutamide, Goserelin
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- University of Washington
Prostatic Neoplasms
The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females
Background: Insomnia is associated with difficulty sleeping. The drug zolpidem is widely prescribed for insomnia. Women have reported worse effects from the drug than men.
- Trial name
- NCT03436745
- Testing
- Zolpidem, ECG
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Breast Cancer
Evaluation of Sleep Quality in Prostate Cancer Patients Undergoing Treatment With Hormonal Therapeutic Approaches and in Patients With Full-resected Early Breast Cancer
This study will use polysomnography, alongside other methodologies such as questionnaires, actigraphic measurements and salivary melatonin samples used in previous studies to investigate sleep quality in patients with i)…
- Trial name
- SIESTA (NCT04543799)
- Testing
- polysomnography, actigraphy, questionnaires
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Prostate Cancer
Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer
For this study, high risk prostate cancer patients with lower risk ARTERA scores will be treated with 6 months of Androgen Deprivation Therapy (ADT) in conjunction with dose escalated radiotherapy to the prostate and nodes.
- Trial name
- NCT07801664
- Testing
- Androgen Deprivation Therapy (ADT), Radiotherapy
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- NYU Langone Health
Prostate Cancer Metastatic
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
The primary objective is to determine the safety and activity of combined hormonal chemoimmunotherapy in a single-arm phase II trial of REGN2810, androgen deprivation therapy (ADT), and docetaxel in patients with newly…
- Trial name
- NCT03951831
- Testing
- REGN2810, Degarelix, Leuprolide Acetate
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Mark Stein
Prostate Cancer
SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00026377
- Testing
- bicalutamide, flutamide, goserelin acetate
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Chicago
Prostate Cancer
A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer
The purpose of this study is to find out whether combining a shorter than standard course of ADT with standard prostate brachytherapy and hypofractionated external beam radiation therapy is a safe and effective way to prevent…
- Trial name
- NCT05100472
- Testing
- Androgen deprivation therapy (ADT), Brachytherapy, Hypofractionated pelvic External beam radiation
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostatic Neoplasms, Exercise
Health Effects of Soccer Training in Men With Prostate Cancer Receiving Androgen Deprivation Therapy
Androgen Deprivation Therapy (ADT) is standard treatment for locally advanced or advanced Prostate Cancer (PC). The musculoskeletal toxicity associated with ADT is well established, leading to a decrease in muscle mass, increased…
- Conditions
- Prostatic Neoplasms, Exercise, Soccer Training, Androgen Deprivation Therapy
- Trial name
- NCT01711892
- Testing
- Soccer training
- Where
- Denmark
- Volunteers
- 57 people
- Sponsor
- University of Copenhagen
Prostate Cancer
A Pilot Study of Physical Activity for Improving Quality of Life in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)
60 eligible subjects will be randomized into one of three study arms 1) aerobic exercise, 2) resistance exercise, or 3) usual care.
- Trial name
- MAP-P (NCT00853164)
- Testing
- walking exercise, weight training, Usual Care
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Washington University School of Medicine
Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Low-volume Metastasis
A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer
This is an observational study in which medical records of Japanese men with low-volume metastatic hormone-sensitive prostate cancer (mHSPC), who received treatment with a combination therapy of darolutamide with an androgen…
- Trial name
- HAYATE (NCT06661122)
- Testing
- Darolutamide (BAY1841788) + docetaxel + ADT
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Bayer
Prostate Cancer
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00005044
- Testing
- Casodex, Eulexin, LHRH agonist
- Where
- 261 sites in United States, Canada
- Volunteers
- 1,579 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer
The purpose of this extension study was to collect long-term safety and tolerability information to support a marketing authorisation application for a three-month dosage regimen of degarelix.
- Trial name
- NCT00268892
- Testing
- Degarelix
- Where
- 23 sites in Belgium, Finland and 8 more
- Volunteers
- 278 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
The goal of this clinical research study is to learn if adding the combination of abiraterone acetate and prednisone with or without enzalutamide to hormonal therapy can help to control prostate cancer when given before surgery.
- Trial name
- NCT01946165
- Testing
- Abiraterone Acetate, Prednisone, Enzalutamide
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center